Horizon Pharma (HZNP) Confirms FDA Advisory Committee Votes Unanimously to Support Use of Teprotumumab for Treatment of Thyroid Eye Disease

Horizon Pharma (HZNP) PT Raised to $41 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Horizon Pharma (NASDAQ: HZNP) to $41.00 (from $39.00) while maintaining an Outperform rating.

The analyst commented, "The Advisory Committee voted unanimously in support of Teprotumumab for the treatment of thyroid eye disease. Importantly, the committee... More

Horizon Pharma (HZNP) Wins FDA Panel Vote for Drug to Treat Eye Disease, Vote 12 to 0

Horizon Pharma (NASDAQ: HZNP) Wins FDA Panel Vote for Drug to Treat Eye Disease, Vote 12 to 0

Horizon Pharma (HZNP) Trading Halted Today for FDA DODAC Meeting to Discuss Teprotumumab for Thyroid Eye Disease

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that NASDAQ has halted trading of the Companys common stock. As per the U.S. Food and Drug Administration (FDA) guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee... More

Horizon Pharma (HZNP) Halted, News Pending

Horizon Pharma (NASDAQ: HZNP) Halted, News Pending

Horizon Pharma (HZNP) Volatile Following FDA Briefing Docs for Teprotumumab

Horizon Pharma (NASDAQ: HZNP) was volatile in morning trade following the posting of the FDA briefing documents for Teprotumumab (here).

After a quick read, Cowen analyst Ken Cacciatore said "Tepro Looks Approvable, Appears FDA Is Seeking Label Input On Various Issues"